Conquering Your ‘Personal Everest’

Milind Soman tells us about I Can You Can, an adventure reality show that he is hosting, and his trekking experience to Everest Base Camp with the contestants

Smoking and Everest Base Camp trekking — two quite unrelated and ironic things in one sentence, aren’t they? Adventure reality show I Can You Can on online video platform Viu combines these two in an interesting manner. Produced by BBC India, I Can You Can, a captivating anti-smoking initiative went online on December 17.

Made in partnership with Nicotex, the six-episode series will be telecast every Sunday. It will be available on Viu and will be televised as a simulcast on National Geographic.

The show is hosted by actor, model and athlete Milind Soman, and showcases the journey of six people, including three who want to quit smoking and three who have already quit. “The interesting part of the journey is the interaction between the smokers and the ones who have quit and their efforts to not just conquer Everest Base Camp, but also their own ‘personal Everests’,” says Milind.

Having time and again raised the bar for fitness and health, Milind says, “Hosting I Can You Can was an exhilarating experience for me. We shot some breathtaking sequences in the unexplored terrains on our way to Everest Camp. I have been a chainsmoker in the past and I could relate to what the contestants of the show have been through. I think when something is so easily accessible and addictive, it just makes it tougher to put a stop to it. I hope with this show, viewers will realise how important a healthy lifestyle is and be encouraged to kick the butt.”

What made him quit smoking, we ask. “I began smoking when I had just entered the industry. Given our hectic schedules, the endless wait at shooting sights and other such things pushed me to begin smoking, given the number of smokers around me. All these years even while I was smoking, I knew it was wrong, always. One fine day, I just thought that I can’t continue this. One bad habit leads to a worse habit and similarly, one good habit leads to a better one. That was it. It wasn’t easy quitting, I took two years to give up completely but I did it and can feel the difference,” he says.

On the show, Milind says that he got an opportunity to interact with the six contenders and learn from them too. With an engaging and contemporary format of an adventure series, the weekly show aims at reaching out to millennials and hopes for each to conquer their own Everest.

“A lot of sharing of experiences happened among all of us,” he says adding that the six contenders on the show were chosen through a contest.

Remind him of the date — December 16, and the coincidence that he recently did a short film on Vijay Diwas — when Pakistani troops surrendered to the Indian Army after the 1964 war, Milind smiles and says, “Yes! I absolutely enjoyed doing that short film and love taking up such interesting projects.” When BBC India approached him with I Can You Can too, he “jumped at the opportunity”, he says.

Ask him about his next immediate plan, and he quickly replies, “Don’t even ask, because I don’t have any. I don’t believe in planning too much. I do what I like and enjoy doing it like that,” he concludes.

This article originally appeared on Sakal Times

For more such blogs follow us on Twitter, Facebook, LinkedIn.

We wish you a very happy 72nd Indian Independence Day!

Seven decades after our historic tryst with destiny, on 15 August 2018, India will celebrate 72 years of independence, democracy and sovereignty. Presenting some interesting snippets from the archives on this occasion.

“India was officially proclaimed independent on 15th August 1947 with much celebrations in Delhi and other towns. Cipla celebrated the first Independence Day by a flag hoisting ceremony where all workers and staff of Cipla were present.”

– Dr. Khwaja Abdul Hamied,
Founder, Cipla.
‘A Life To Remember – An Autobiography’ (1972)

This is how India’s first Independence Day was celebrated by Cipla. The tricoloured Indian national flag was proudly unfurled and hoisted and the venue was Cipla’s very first manufacturing site and headquarters in Mumbai Central.

Seen here, Cipla Founder, Dr. K.A. Hamied, with his two young sons Dr. Y.K. Hamied and Mr. M.K. Hamied along with the factory staff and workers.

Cipla’s celebration of Indian independence did not end there. As a nationalist and freedom fighter, Dr. K.A. Hamied ensured that Cipla as an employer played its part in making the occasion unforgettable for Ciplaites by announcing a generous Independence Bonus!

The late Dr. A.R. Kidwai was a multi-faceted personality – public servant, scholar, statesman extraordinaire of post-independence India. Dr. Kidwai was a Cipla chemist from 1941 to 1945 and was witness to early scientific projects of Cipla as well as the involvement of then Ciplaites in the independence movement. Here’s a snippet of his reflections from the Oral History collection of the archives.

This advertisement placed by Cipla in the 1948 edition of the journal, Marg is a strong reminder of how Cipla was a trail-blazer in pharma R&D, quality and manufacturing in India, and saw itself as second to none. Spend a minute or two to read it with its context in mind – a time of euphoria, great promise, unrealised potential. A time when the state of India would finally attain equality in status with others on the world stage. Cipla’s strides were a microcosm of India’s in so many ways.

On that note, we wish you a very happy 72nd Indian Independence Day!

Cipla Receives Final Approval for Generic Reyataz® (Atazanavir Caps 100mg, 150mg, 200mg, 300mg)

Press Release

Cipla Limited (“Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Atazanavir Caps 100mg, 150mg, 200mg, 300mg from the United States Food
and Drug Administration (US FDA).

Cipla’s Atazanavir Caps 100mg, 150mg, 200mg, 300mg is AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s, Reyataz®. It is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients with minimum age of 6 years and older weighing at least 15 kg.

According to IQVIA (IMS Health), Reyataz® and its generic equivalents had US sales of approximately $324M for the 12-month period ending April 2018.

For more such blogs follow us on TwitterFacebookLinkedIn.

Cipla partners with MSN Laboratories for marketing and distribution of generic Xeloda® (Capecitabine Tabs 150mg and 500mg)

Press Release

Cipla USA, Inc., (“Cipla”) a subsidiary of Cipla Limited, today announced that it has secured rights from MSN Laboratories Private Limited to market & distribute Capecitabine 150mg and 500mg tablets in the United States of America. The product is available immediately.

The Capecitabine 150mg and 500mg tablet is an AB-rated generic therapeutic equivalent version of Genentech’s Xeloda®. Capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with Dukes C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred, and also indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.

As per IQVIA (IMS Health), Xeloda® and its generic equivalents had sales of approximately $178M for the 12-month period ending June 2018 in the United States.

About MSN Group
Founded in 2003 with a mission to make health care affordable, the MSN Group based out of Hyderabad is one of the fastest growing research-based pharmaceutical company in India. MSN has 10 API (including Oncology) and
five finished dosage facilities out of which three in Hyderabad, one both in USA & Myanmar. MSN Labs has an integrated R&D Center for both API and product formulation under one roof. The company’s core strategy will be to focus on high barrier of entry & first to market paragraph 4 products. MSN customer base exceeds 250 customers with a global presence in 65 countries throughout US, Europe, Latin America, Middle-East, Asia Pacific, Africa and CIS markets. With more than 350 National & International patents filed, MSN’s product basket offers 300 APIs & 200 Formulations covering 35 major therapies.

For more such blogs follow us on TwitterFacebookLinkedIn.

Cipla Receives USFDA Approval for Generic Voltaren® Gel (Diclofenac Sodium Topical Gel, 1%)

Press Release

Cipla Limited (“Cipla”) announced that it has received final approval on August 3, 2018, for its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium Topical Gel, 1% from the United States Food and Drug Administration (US FDA).

Cipla’s Diclofenac Sodium Topical Gel, 1% is AB-rated generic therapeutic equivalent to the reference listed drug (RLD), Voltaren® Gel, 1% of GlaxoSmithKline Consumer Health®. It is a non-steroidal anti-inflammatory drug
indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands.

According to IQVIA (IMS Health), Voltaren® Gel and its generic equivalents had US sales of approximately $353M for the 12-month period ending June 2018. The product will be available for shipping in the US in the upcoming week.

For more such blogs follow us on TwitterFacebookLinkedIn.